Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
A phase 2/3 trial of Futibatinib, Fulvestrant in metastatic cancer, run by Taiho Oncology, Inc., active and no longer recruiting.
Overview
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. is a phase 2/3 interventional study registered as NCT06506955 by Taiho Oncology, Inc., with 15 participants planned, started 2024-10-01 and due to reach its primary completion in 2027-04. Interventions recorded: futibatinib, futibatinib, fulvestrant. Conditions listed: Advanced/Metastatic Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialPhase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
Shares Fulvestrant, Metastatic cancer (cancer that has spread).
- TrialPhase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Shares Fulvestrant, Metastatic cancer (cancer that has spread).
- TrialSNV4818 in Participants With Advanced Solid Tumors
Shares Fulvestrant, Metastatic cancer (cancer that has spread).
- TrialEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Shares Fulvestrant, Metastatic cancer (cancer that has spread).
- TrialPhase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients
Shares Fulvestrant, Metastatic cancer (cancer that has spread).
- TrialOpen-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Shares Fulvestrant, Metastatic cancer (cancer that has spread).
- TrialCapivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
Shares Fulvestrant, Metastatic cancer (cancer that has spread).
- TrialA Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain
Shares Fulvestrant, Metastatic cancer (cancer that has spread).